Antibody Drug Conjugates Contract Manufacturing Market by Linker (Cleavable, Non-cleavable), Condition (Breast Cancer, Lymphoma, Myeloma), End Use - Global Forecast 2024-2030
The Antibody Drug Conjugates Contract Manufacturing Market size was estimated at USD 11.88 billion in 2023 and expected to reach USD 13.06 billion in 2024, at a CAGR 11.82% to reach USD 25.99 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Antibody Drug Conjugates Contract Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Drug Conjugates Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Antibody Drug Conjugates Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., ADC Therapeutics SA., AstraZeneca PLC, Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories, Axplora, Catalent, Inc., Creative Biolabs, Daiichi Sankyo, EirGenix, Inc., Gilead Sciences, GlaxoSmithKline PLC, ImmunoGen, Inc., Merck KgaA, Mersana Therapeutics, MicroBiopharm Japan Co., Ltd., Pfizer Inc., Pierre Fabre S.A, Piramal Pharma Solutions, Recipharm AB, Regeneron Pharmaceuticals, Inc., Samsung Biologics, Sanofi, and Sartorius AG.
Market Segmentation & Coverage
This research report categorizes the Antibody Drug Conjugates Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:
Linker
Cleavable
Breast Cancer
Clinical Trial
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Antibody Drug Conjugates Contract Manufacturing Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Drug Conjugates Contract Manufacturing Market?
- What are the technology trends and regulatory frameworks in the Antibody Drug Conjugates Contract Manufacturing Market?
- What is the market share of the leading vendors in the Antibody Drug Conjugates Contract Manufacturing Market?
- Which modes and strategic moves are suitable for entering the Antibody Drug Conjugates Contract Manufacturing Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Antibody Drug Conjugates Contract Manufacturing Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing outsourcing by biopharmaceutical companies
- 5.1.1.2. Surging number of CMOs and ongoing R&D activities
- 5.1.1.3. Growing demand for ADC amid high prevalence of chronic disease
- 5.1.2. Restraints
- 5.1.2.1. High cost of setting up a production facility for antibody-drug conjugates
- 5.1.3. Opportunities
- 5.1.3.1. Surge in ADC approvals from regulatory bodies
- 5.1.3.2. Expanding investments in advanced manufacturing technologies
- 5.1.4. Challenges
- 5.1.4.1. Stringent regulatory requirements for CMOs
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Antibody Drug Conjugates Contract Manufacturing Market, by Linker
- 6.1. Introduction
- 6.2. Cleavable
- 6.3. Non-cleavable
- 7. Antibody Drug Conjugates Contract Manufacturing Market, by Condition
- 7.1. Introduction
- 7.2. Breast Cancer
- 7.3. Lymphoma
- 7.4. Myeloma
- 8. Antibody Drug Conjugates Contract Manufacturing Market, by End Use
- 8.1. Introduction
- 8.2. Clinical Trial
- 8.3. Myeloma Treatment
- 9. Americas Antibody Drug Conjugates Contract Manufacturing Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Antibody Drug Conjugates Contract Manufacturing Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. AbbVie Inc.
- 13.1.2. ADC Therapeutics SA.
- 13.1.3. AstraZeneca PLC
- 13.1.4. Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories
- 13.1.5. Axplora
- 13.1.6. Catalent, Inc.
- 13.1.7. Creative Biolabs
- 13.1.8. Daiichi Sankyo
- 13.1.9. EirGenix, Inc.
- 13.1.10. Gilead Sciences
- 13.1.11. GlaxoSmithKline PLC
- 13.1.12. ImmunoGen, Inc.
- 13.1.13. Merck KgaA
- 13.1.14. Mersana Therapeutics
- 13.1.15. MicroBiopharm Japan Co., Ltd.
- 13.1.16. Pfizer Inc.
- 13.1.17. Pierre Fabre S.A
- 13.1.18. Piramal Pharma Solutions
- 13.1.19. Recipharm AB
- 13.1.20. Regeneron Pharmaceuticals, Inc.
- 13.1.21. Samsung Biologics
- 13.1.22. Sanofi
- 13.1.23. Sartorius AG
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
- FIGURE 2. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
- FIGURE 3. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DYNAMICS
- FIGURE 7. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2023 VS 2030 (%)
- FIGURE 8. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2023 VS 2030 (%)
- FIGURE 10. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2023 VS 2030 (%)
- FIGURE 12. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook